Novartis AG $NVS Shares Sold by HF Advisory Group LLC

HF Advisory Group LLC decreased its position in shares of Novartis AG (NYSE:NVS) by 28.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,551 shares of the company’s stock after selling 3,463 shares during the quarter. HF Advisory Group LLC’s holdings in Novartis were worth $1,340,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Arlington Trust Co LLC purchased a new stake in Novartis during the fourth quarter worth $25,000. Archer Investment Corp grew its holdings in Novartis by 93.0% in the first quarter. Archer Investment Corp now owns 166 shares of the company’s stock valued at $25,000 after purchasing an additional 80 shares during the last quarter. CrossGen Wealth LLC purchased a new position in shares of Novartis in the fourth quarter valued at $28,000. Bank of Jackson Hole Trust increased its position in shares of Novartis by 425.0% in the fourth quarter. Bank of Jackson Hole Trust now owns 231 shares of the company’s stock valued at $32,000 after buying an additional 187 shares in the last quarter. Finally, Measured Wealth Private Client Group LLC acquired a new position in shares of Novartis during the 3rd quarter worth $33,000. 13.12% of the stock is owned by hedge funds and other institutional investors.

Novartis Stock Performance

Shares of NYSE NVS opened at $156.38 on Friday. The company has a 50-day simple moving average of $152.99 and a 200-day simple moving average of $153.11. The company has a debt-to-equity ratio of 0.89, a current ratio of 0.86 and a quick ratio of 0.67. The company has a market cap of $298.40 billion, a PE ratio of 23.59, a price-to-earnings-growth ratio of 2.67 and a beta of 0.45. Novartis AG has a 12 month low of $115.75 and a 12 month high of $170.46.

Novartis (NYSE:NVS) last announced its quarterly earnings data on Tuesday, June 30th. The company reported $2.41 earnings per share (EPS) for the quarter. Novartis had a net margin of 23.29% and a return on equity of 38.56%. The business had revenue of $14.95 billion for the quarter. On average, equities analysts anticipate that Novartis AG will post 8.86 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on NVS shares. Weiss Ratings reiterated a “buy (b)” rating on shares of Novartis in a research report on Friday, July 24th. Citigroup restated a “buy” rating on shares of Novartis in a report on Wednesday, July 22nd. Seven investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $141.20.

Novartis Company Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.